Riverbridge Partners LLC Increases Stock Holdings in Abbott Laboratories $ABT

Riverbridge Partners LLC boosted its stake in Abbott Laboratories (NYSE:ABT) by 61.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,987 shares of the healthcare product maker’s stock after buying an additional 6,459 shares during the quarter. Riverbridge Partners LLC’s holdings in Abbott Laboratories were worth $1,744,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ABT. Richards Merrill & Peterson Inc. grew its position in Abbott Laboratories by 9.1% in the 1st quarter. Richards Merrill & Peterson Inc. now owns 10,439 shares of the healthcare product maker’s stock worth $1,072,000 after purchasing an additional 871 shares in the last quarter. New Covenant Trust Company N.A. lifted its position in shares of Abbott Laboratories by 16.5% during the 1st quarter. New Covenant Trust Company N.A. now owns 3,019 shares of the healthcare product maker’s stock worth $310,000 after buying an additional 428 shares in the last quarter. Bar Harbor Wealth Management boosted its stake in shares of Abbott Laboratories by 0.7% in the 1st quarter. Bar Harbor Wealth Management now owns 140,099 shares of the healthcare product maker’s stock worth $14,384,000 after buying an additional 996 shares during the last quarter. Coerente Capital Management grew its holdings in shares of Abbott Laboratories by 2.2% in the first quarter. Coerente Capital Management now owns 226,208 shares of the healthcare product maker’s stock valued at $23,225,000 after acquiring an additional 4,801 shares in the last quarter. Finally, HHM Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories by 7.6% in the first quarter. HHM Wealth Advisors LLC now owns 5,900 shares of the healthcare product maker’s stock valued at $606,000 after acquiring an additional 418 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott signed a global licensing agreement with ALZpath to incorporate its pTau217 antibody into a blood-based Alzheimer’s diagnostic, a potentially meaningful addition to Abbott’s diagnostics portfolio. Reuters article
• Positive Sentiment: Reports highlighted growing momentum in Abbott’s emerging markets and EPD business, supported by branded generics demand, biosimilar expansion, and new approvals, which points to continued international growth. Article
• Positive Sentiment: MiniMed’s launch of Abbott Instinct sensors across European markets expands Abbott’s diabetes technology reach and reinforces the company’s connected care ecosystem. Article
• Positive Sentiment: Abbott was also featured in bullish commentary as a durable dividend aristocrat with 54 straight years of dividend increases, which may be supporting investor sentiment around the stock. Article
• Neutral Sentiment: Abbott continued to draw investor and analyst attention, with articles noting strong interest and a “Moderate Buy” consensus, but these are more sentiment indicators than new fundamental developments. Zacks article
• Negative Sentiment: A Missouri appeals court decision allowing Abbott’s $495 million preterm baby formula verdict appeal to remain in place keeps a major legal overhang on the shares. Article

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ABT shares. Evercore dropped their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. TD Cowen decreased their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Sanford C. Bernstein reduced their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $90.46 on Thursday. The company has a market capitalization of $157.56 billion, a P/E ratio of 25.34, a P/E/G ratio of 1.56 and a beta of 0.63. The business has a fifty day simple moving average of $89.39 and a two-hundred day simple moving average of $105.69. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $138.84.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the company earned $1.09 EPS. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.